Research Triangle Park, NC (PRWEB) June 19, 2013
North Carolina-based life sciences company Entegrion, Inc., announced organizational changes to advance development of its technologies.
Entegrion’s Executive Chairman John B. Mowell said, “To support the advanced development of our product candidates Entegrion’s Board of Directors has made changes to the Company’s management structure and engaged industry leaders as key advisors.”
The Company announced that Michael Galiger will serve as Vice President of Operations with primary responsibility for development of Entegrion’s plasma product Resusix, as well as supporting the continued advancement of the Company’s other technologies. “Mike’s technical background, intensive work with the development of Entegrion’s products, and his success in attracting a solid product development team, including Stacy Hammonds as Director of Clinical Operations, and Taegen Sullivan, Product Development Engineer, have made a substantial contribution to Entegrion’s success,” Mowell continued.
Entegrion also announced the formation of a clinical advisory Board initially comprised of Paul Ness, MD, Director of Transfusion Medicine at Johns Hopkins; Professor Peter Rhee, MD, Chief of Trauma, Critical Care, Burns and Emergency Surgery, University of Arizona; Edward Scott, MD, President of Key Biologics; and Philip C. Spinella, MD, Director, Pediatric Critical Care Translational Research Program, Washington University, St. Louis.
“We are immensely proud to be associated with these world-class leaders in transfusion and trauma medicine. Drs. Rhee and Spinella both came out of the Armed Forces and served in Iraq. They will bring a unique ‘user perspective’ to our technologies. Dr. Scott has decades of experience with the supply of blood and blood derivatives, and Dr. Ness is an expert
Copyright©2012 Vocus, Inc.
All rights reserved